NYSE American - Delayed Quote USD

Zomedica Corp. (ZOM)

0.1330 +0.0029 (+2.23%)
At close: April 26 at 4:00 PM EDT
0.1338 +0.00 (+0.60%)
After hours: April 26 at 7:56 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
25,186.0000
25,186.0000
18,930.0000
4,133.0000
--
Cost of Revenue
7,868.0000
7,868.0000
5,462.0000
1,079.0000
--
Gross Profit
17,318.0000
17,318.0000
13,468.0000
3,054.0000
--
Operating Expense
48,910.0000
48,910.0000
35,391.0000
24,428.0000
16,764.9780
Operating Income
-31,592.0000
-31,592.0000
-21,923.0000
-21,374.0000
-16,764.9780
Net Non Operating Interest Income Expense
5,283.0000
5,283.0000
2,700.0000
351.0000
32.1270
Other Income Expense
-9,551.0000
-9,551.0000
-158.0000
306.0000
-178.9330
Pretax Income
-35,860.0000
-35,860.0000
-19,381.0000
-20,717.0000
-16,911.7840
Tax Provision
-1,331.0000
-1,331.0000
-2,366.0000
-2,333.0000
--
Net Income Common Stockholders
-34,529.0000
-34,529.0000
-17,015.0000
-50,423.0000
-16,911.7840
Diluted NI Available to Com Stockholders
-34,529.0000
-34,529.0000
-17,015.0000
-50,423.0000
-16,911.7840
Basic EPS
-0.04
--
-0.02
-0.05
-0.05
Diluted EPS
-0.04
--
-0.02
-0.05
-0.05
Basic Average Shares
979,949.6680
--
979,949.6680
956,533.7610
364,444.6640
Diluted Average Shares
979,949.6680
--
979,949.6680
956,533.7610
364,444.6640
Total Operating Income as Reported
-31,592.0000
-31,592.0000
-21,923.0000
-21,374.0000
-16,764.9780
Rent Expense Supplemental
--
--
--
--
299.9470
Total Expenses
56,778.0000
56,778.0000
40,853.0000
25,507.0000
16,764.9780
Net Income from Continuing & Discontinued Operation
-34,529.0000
-34,529.0000
-17,015.0000
-18,384.0000
-16,911.7840
Normalized Income
-23,329.7028
-23,329.7028
-16,882.4338
-18,609.3963
-16,724.2500
Interest Income
5,458.0000
5,458.0000
2,701.0000
357.0000
32.8590
Interest Expense
175.0000
175.0000
1.0000
6.0000
0.7320
Net Interest Income
5,283.0000
5,283.0000
2,700.0000
351.0000
32.1270
EBIT
-35,685.0000
-35,685.0000
-19,380.0000
-20,711.0000
-16,911.0520
EBITDA
-29,387.0000
-29,387.0000
-15,338.0000
-19,572.0000
-16,381.0320
Reconciled Cost of Revenue
7,868.0000
7,868.0000
5,462.0000
1,079.0000
--
Reconciled Depreciation
6,298.0000
6,298.0000
4,042.0000
1,139.0000
530.0200
Net Income from Continuing Operation Net Minority Interest
-34,529.0000
-34,529.0000
-17,015.0000
-18,384.0000
-16,911.7840
Total Unusual Items Excluding Goodwill
-11,631.0000
-11,631.0000
-151.0000
254.0000
-187.5340
Total Unusual Items
-11,631.0000
-11,631.0000
-151.0000
254.0000
-187.5340
Normalized EBITDA
-17,756.0000
-17,756.0000
-15,187.0000
-19,826.0000
-16,193.4980
Tax Rate for Calcs
0.0000
0.0000
0.0001
0.0001
--
Tax Effect of Unusual Items
-431.7028
-431.7028
-18.4338
28.6037
--
12/31/2020 - 11/21/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SENS Senseonics Holdings, Inc.
0.4157
-0.60%
 
BIOL BIOLASE, Inc.
0.1480
0.00%
 
SINT Sintx Technologies, Inc.
0.0404
+10.38%
 
ASXC Asensus Surgical, Inc.
0.2490
+3.32%
 
NUWE Nuwellis, Inc.
0.1678
-41.94%
 
HSCS Heart Test Laboratories, Inc.
0.0974
-2.50%
 
CATX Perspective Therapeutics, Inc.
1.5800
-1.25%
 
NSPR InspireMD, Inc.
2.0000
+5.82%
 
DYNT Dynatronics Corporation
0.5549
-3.53%
 
PACB Pacific Biosciences of California, Inc.
1.4700
+6.52%